This submission is currently stalled and awaiting further input from the submitter.
Y90 radioembolization followed by intravenous Nivolumab for advanced hepatocellular carcinoma
To evaluate the efficacy of combination therapy with ICI and RT in patients, a Phase II trial (CA209-678) was conducted to investigate the efficacy and safety of Y90-RE followed by nivolumab in patients with advanced HCC (NCT03033446, n = 36). Interestingly, the ORR was found to be 30.6% in all patients and 43.5% when restricted to patients with only intrahepatic tumors, suggesting possible synergism between Y90-RE and ICI. Here we present whole exome sequencing (WES) and RNA-seq data for 33 patients treated with Y90 radioembolization followed with Nivolumab.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
| Publications | Citations |
|---|---|
|
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.
J Immunother Cancer 11: 2023 e007106 |
1 |